1. Home
  2. NEO vs MNKD Comparison

NEO vs MNKD Comparison

Compare NEO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$15.11

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.40

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEO
MNKD
Founded
2001
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2008
2004

Fundamental Metrics

Financial Performance
Metric
NEO
MNKD
Price
$15.11
$4.40
Analyst Decision
Strong Buy
Buy
Analyst Count
8
8
Target Price
$13.38
$8.69
AVG Volume (30 Days)
3.4M
4.8M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
$10.63
$35.81
Revenue Next Year
$9.73
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$4.72
$2.23
52 Week High
$15.56
$6.51

Technical Indicators

Market Signals
Indicator
NEO
MNKD
Relative Strength Index (RSI) 83.10 69.91
Support Level $11.49 $3.77
Resistance Level N/A $6.12
Average True Range (ATR) 0.70 0.22
MACD 0.33 0.03
Stochastic Oscillator 92.82 97.24

Price Performance

Historical Comparison
NEO
MNKD

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: